Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sacituzumab govitecan versus physician's choice chemotherapy in HR-positive/HER2-negative advanced breast cancer after endocrine therapy
2022-502593-17-00Phase 3Authorised
- Sponsor
- Gilead Sciences
- Start
- Sep 2023
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 28
01
Overview
Phase 3, randomised, open-label trial of sacituzumab govitecan in breast cancer (2 arms), sponsored by Gilead Sciences. Primary endpoint: Progression-free survival by blinded independent central review. Planned start Sep 2023; status: authorised.
02
Drugs
sacituzumab govitecan
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2022-502593-17-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502593-17-00.